Pneumococcal Vaccine Market to Grow with a CAGR of 6.26% through 2030F

Expanded immunization programs, augmented healthcare spending, and government support are expected to drive the Global Pneumococcal Vaccine Market growth in the forecast period, 2025-2030

According to TechSci Research report, “Pneumococcal Vaccine Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2030F”, the Global Pneumococcal Vaccine Market stood at USD 9.63 billion in 2024 and is anticipated to grow with a CAGR of 6.26% in the forecast period, 2025-2030. This can be attributed to synergistic global efforts. Collaboration between pharmaceutical firms, non-profit organizations, and international agencies has played a pivotal role in expanding vaccine access, especially in underserved regions. Initiatives like Gavi, the Vaccine Alliance, have facilitated the distribution of pneumococcal vaccines to resource-constrained areas, further propelling market growth.

Sophisticated surveillance systems and data analytics are becoming indispensable tools for monitoring pneumococcal disease trends. Real-time data collection and analysis enable healthcare authorities to respond promptly to outbreaks and allocate resources more effectively.

Factors such as the rising burden of pneumonia cases, government-driven awareness programs for pneumonia immunization, and the introduction of innovative pneumococcal vaccines are expected to drive market growth in the forecast period. For instance, in March 2022, the Ministry of Health and Family Welfare launched the SAANS (Social Awareness and Actions to Neutralize Pneumonia Successfully) Initiative as part of the National Health Mission's efforts to reduce childhood pneumonia-related deaths in both rural and urban areas. This initiative is anticipated to exhibit substantial growth potential in the coming years.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Pneumococcal Vaccine Market”

The Global Pneumococcal Vaccine Market is segmented into type, indication, product, distribution, regional distribution, and company.

Based on its type, conjugate vaccines are experiencing faster growth compared to polysaccharide vaccines. This trend is primarily due to the broader and more robust immune protection offered by conjugate vaccines, which are effective across various age groups, including infants and the elderly. Conjugate vaccines elicit a strong and long-lasting immune response by linking polysaccharides to a protein carrier, enhancing immunogenicity. The inclusion of conjugate vaccines in national immunization programs and their proven efficacy in reducing invasive pneumococcal diseases have further propelled their adoption and market expansion.

Based on region, the Asia-Pacific region is experiencing the fastest growth in the global pneumococcal vaccine market due to several key factors. Rapid urbanization and economic development have improved healthcare infrastructure and increased access to medical services, enabling broader vaccine distribution. Government initiatives and expanded immunization programs have heightened awareness of pneumococcal disease prevention, leading to higher vaccination rates. The region's large and growing population, particularly in countries like China and India, presents a substantial target demographic for vaccination efforts. These combined factors contribute to the accelerated expansion of the pneumococcal vaccine market in the Asia-Pacific region.

Major companies operating in Global Pneumococcal Vaccine Market are:

·         GSK PLC

·         Pfizer Inc

·         Merck KGaA

·         Serum Institute of India Pvt Ltd

·         CSL Ltd

·         Sanofi SA

·         Walvax Biotechnology Co., Ltd

·         Beijing Minhai Biotechnology Limited Company

·         AstraZeneca PLC

·         BioNTech SE

Download Free Sample Report

Customers can also request for 10% free customization on this report.

“The global pneumococcal vaccine market is on the brink of a new era characterized by groundbreaking trends that promise to reshape vaccination strategies and outcomes. From next-generation vaccines offering broader protection to tailored solutions for various populations, the market is evolving to meet the dynamic challenges posed by pneumococcal diseases,” said Mr. Karan Chechi, Research Director of TechSci Research, a research-based management consulting firm.

“Pneumococcal Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Conjugate Vaccines, Polysaccharide Vaccines), By Indication (Bronchitis, Meningitis, Pneumonia, Sepsis), By Product (Pneumovax23, Prevnar 13, Synflorix), By Distribution (Government Authorities, Non-Governmental Organizations), By Region & Competition, 2020-2030F”, has evaluated the future growth potential of Global Pneumococcal Vaccine Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Pneumococcal Vaccine Market.

Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: sales@techsciresearch.com

Website: www.techsciresearch.com